![Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial - The Lancet HIV Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial - The Lancet HIV](https://www.thelancet.com/cms/asset/2c1be0be-ecd5-4bee-8c1a-b5e7bafc493b/gr2.jpg)
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial - The Lancet HIV
![Honor: Writer Paulina Chiziane winner of the prestigious Camões Award - Portugal - Portuguese American Journal Honor: Writer Paulina Chiziane winner of the prestigious Camões Award - Portugal - Portuguese American Journal](https://portuguese-american-journal.com/wp-content/uploads/2021/10/Screen-Shot-2021-10-20-at-6.23.44-PM.png)
Honor: Writer Paulina Chiziane winner of the prestigious Camões Award - Portugal - Portuguese American Journal
![Sophie Ngo email address & phone number | Olympus Life Science Territory Manager Microscopy contact information - RocketReach Sophie Ngo email address & phone number | Olympus Life Science Territory Manager Microscopy contact information - RocketReach](https://d1hbpr09pwz0sk.cloudfront.net/profile_pic/sophie-my-hang-ngo-0bd9517e.jpg)
Sophie Ngo email address & phone number | Olympus Life Science Territory Manager Microscopy contact information - RocketReach
![Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial - The Lancet HIV Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial - The Lancet HIV](https://www.thelancet.com/cms/attachment/bd33fa93-e2f2-4339-82d1-b47fdeca8fbe/gr1.gif)
Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial - The Lancet HIV
![Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study - The Lancet HIV Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study - The Lancet HIV](https://www.thelancet.com/cms/asset/ebd68556-14e2-4177-aa36-575da598e2d1/gr1.jpg)
Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study - The Lancet HIV
![The Impact of an Intervention to Improve Malaria Care in Public Health Centers on Health Indicators of Children in Tororo, Uganda (PRIME): A Cluster-Randomized Trial in: The American Journal of Tropical Medicine The Impact of an Intervention to Improve Malaria Care in Public Health Centers on Health Indicators of Children in Tororo, Uganda (PRIME): A Cluster-Randomized Trial in: The American Journal of Tropical Medicine](https://www.ajtmh.org/view/journals/tpmd/95/2/full-358fig1.jpg)